CHPA Regulatory Conference to Discuss Advancing Consumer Health with FDA, Other Experts

Event will include regulators, thought-leaders, and stakeholders

Washington, D.C. (April 14, 2017) –  The Consumer Healthcare Products Association (CHPA) will hold its 2017 Regulatory, Scientific & Quality (RSQ) Conference on Thursday, May 11 to Friday, May 12 in North Bethesda, Md.

The annual event, which brings together academic, industry, and regulatory experts to discuss topics affecting the consumer healthcare products industry, will host Janet Woodcock, M.D., director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA). Dr. Woodcock will share insights and observations on the state of regulatory, scientific, and quality issues affecting over-the-counter (OTC) medicines, as well as her perspective on OTC Monograph reform. FDA will provide additional insights during a closing panel, providing an insider’s view on their achievements, future initiatives, and issues affecting the OTC medicine industry. 

In addition to Dr. Woodcock and other FDA representatives, an impressive line-up of speakers and panelists from many organizations will be participating in the event, including the Federal Trade Commission (FTC), Centers for Disease Control and Prevention (CDC), U.S. Pharmacopeia Convention (USP), as well as industry and academic experts. A full list of speakers and an agenda can be found here. Click here for additional information or to register for the conference.

Highlights of the agenda include:

  • The Critical Value of Quality - Dinesh Thakur, chairman, Medassure Global Compliance Corporation
  • Technology’s Impact on Advancing Consumer Self-Care - Bertalan Mesko, Ph.D., The Medical Futurist
  • Science, Policy & Politics - Susan F. Wood, Ph.D., associate professor of health policy and management, George Washington University Milken Institute School of Public Health; Erin Haas, local programs manager, overdose prevention, Maryland Department of Health and Mental Hygiene

Various Panels:

  • Update on OTC Monograph Reform
  • Rx-to-OTC Switch: Translating Technology-Based Innovations into Product Approval and Competitive Differentiation
  • Quality Metrics Programs
  • OTC Advertising Compliance: Past, Present & Future
  • Atypical Actives/Inert Ingredients: Exploring the Current Situation
  • Consumer Healthcare Initiatives in the Digital World
  • Considerations for Human Factors Validation Studies for OTC products
  • Current Issues in Manufacturing: Opportunities & Challenges

Update from the U.S. Centers for Disease Control and Prevention - Daniel S. Budnitz, M.D., director, Medication Safety Program, Division of Healthcare Quality Promotion, U.S. Centers for Disease Control and Prevention

FDA Closing Panel - Michael Kopcha, Ph.D., director, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA; Theresa M. Michele, M.D., director, Division of Nonprescription Drug Products, Office of Drug Evaluation IV, Center for Drug Evaluation and Research, FDA; John Pace (Brad), J.D., director, Division of Nonprescription Drugs and Health Fraud, Office of Compliance, Center for Drug Evaluation and Research, FDA


The Consumer Healthcare Products Association (CHPA) is the 136-year-old national trade association representing the leading manufacturers and marketers of over-the-counter (OTC) medicines and dietary supplements. Every dollar spent by consumers on OTC medicines saves the U.S. healthcare system $6-$7, contributing a total of $102 billion in savings each year. CHPA is committed to empowering self-care by preserving and expanding choice and availability of consumer healthcare products.


Mary Leonard (